MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

MDT

89.97

+2.2%↑

Search

West Pharmaceutical Services Inc

Cerrado

Sector Salud

210.49 3.52

Resumen

Variación precio

24h

Actual

Mínimo

207.9

Máximo

210.49

Métricas clave

By Trading Economics

Ingresos

-5.9M

130M

Ventas

1.9M

749M

P/B

Media del Sector

30.313

73.394

BPA

1.82

Rentabilidad por dividendo

0.41

Margen de beneficio

17.374

EBITDA

-2.1M

203M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+51.73 upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.41%

3.09%

Próximas Ganancias

24 abr 2025

Fecha Próximo Dividendo

7 may 2025

Próxima Fecha de Ex Dividendo

30 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-10B

15B

Apertura anterior

206.97

Cierre anterior

210.49

Noticias sobre sentimiento de mercado

By Acuity

90%

10%

373 / 393 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

West Pharmaceutical Services Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

22 feb 2025, 00:16 UTC

Acciones populares

Stocks to Watch: Alamos Gold, Booking Holdings

22 feb 2025, 16:33 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 15:15 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 14:32 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:49 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

22 feb 2025, 13:22 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Berkshire Operating Earnings Rose 71% to $14.5 Billion in Fourth Quarter -- Barrons.com

21 feb 2025, 23:22 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- Update

21 feb 2025, 23:20 UTC

Ganancias

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

21 feb 2025, 22:34 UTC

Charlas de Mercado

L'Oréal Cuts Exposure to Chinese Market, Grows Emerging Markets -- Market Talk

21 feb 2025, 22:12 UTC

Principales Noticias

DOJ Investigates Medicare Billing Practices at UnitedHealth -- 2nd Update

21 feb 2025, 21:54 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- 2nd Update

21 feb 2025, 21:51 UTC

Ganancias

Tesla Stock Falls. Recalls and Rivian Are in the News. -- Barrons.com

21 feb 2025, 21:50 UTC

Charlas de Mercado
Ganancias

Financial Services Roundup: Market Talk

21 feb 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

21 feb 2025, 21:50 UTC

Principales Noticias

DOGE Aide's IRS Access Won't Include Personal Information -- WSJ

21 feb 2025, 21:48 UTC

Charlas de Mercado
Ganancias

L'Oréal Tops Estée Lauder in Luxury U.S. Market, CEO Says -- Market Talk

21 feb 2025, 21:35 UTC

Charlas de Mercado

Bulk of U.S. Imports From Canada Used to Make U.S. Goods -- Market Talk

21 feb 2025, 21:28 UTC

Principales Noticias

Why Is Warren Buffett Hoarding So Much Cash? -- Update

21 feb 2025, 21:24 UTC

Principales Noticias

Major U.S. Stock Indexes Give Up Gains From the Week -- WSJ

21 feb 2025, 21:19 UTC

Charlas de Mercado

Mexico's Inflation Seen Up in Early February -- Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

21 feb 2025, 20:15 UTC

Charlas de Mercado

JPMorgan Chase Branch Expansion Portends Deposit Growth -- Market Talk

21 feb 2025, 20:05 UTC

Charlas de Mercado

Oil Futures Retreat Into the Weekend Again -- Market Talk

21 feb 2025, 19:58 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Gain -- Market Talk

21 feb 2025, 19:29 UTC

Charlas de Mercado

Gold Slides After Finding Record High -- Market Talk

21 feb 2025, 19:26 UTC

Principales Noticias

Major U.S. Stock Indexes Slip; UnitedHealth Pulls Down DJIA -- WSJ

21 feb 2025, 19:05 UTC

Charlas de Mercado

Business Conditions Seen as Favoring Corporate Credit -- Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

21 feb 2025, 19:02 UTC

Charlas de Mercado

Corporate Credit Expected to Be Hit Unevenly by Trade Wars -- Market Talk

21 feb 2025, 19:00 UTC

Charlas de Mercado

Long-Term Treasury Yields Expected to Rise -- Market Talk

Comparación entre iguales

Cambio de precio

West Pharmaceutical Services Inc Esperado

Precio Objetivo

By TipRanks

51.73% repunte

Estimación a 12 meses

Media 309 USD  51.73%

Máximo 400 USD

Mínimo 250 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para West Pharmaceutical Services Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

201.86 / 322.4Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

373 / 393 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. is a global manufacturer in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. Its products include various primary packaging, containment solutions, reconstitution, and transfer systems, and drug delivery systems, as well as contract manufacturing, analytical lab services, and integrated solutions. The Company’s segments include Proprietary Products and Contract-Manufactured Products. Proprietary Products reportable segment offers proprietary packaging, containment, and drug delivery products, along with analytical lab services and other integrated services. Contract-Manufactured Products segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.